2. Some evidence supports the benefit of probiotics on reducing necrotizing enterocolitis in preterm infants, yet questions remain about their routine clinical use in this setting. Which of the following are unresolved questions that clinicians and practices should consider before using probiotics for necrotizing enterocolitis as routine therapy?
a) Currently available commercial probiotics lack regulation oversight so the quality of each probiotic is not evident by its label.
b) Some infants are too small in size and weight to administer probiotics.
c) The safety of introducing live microorganisms to immature infants and case reports of probiotic-associated sepsis
d) All of the above
e) A and C